John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events ...

Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, is scheduled to ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

NDAQ:BCRX) BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) ...

As expected for a growth strategy, most of the assets tend to be invested in the technology, healthcare ... the vast majority of her 20 years at J.P. Morgan on this team as an analyst and then ...

Tony Lee joined the value team in 2018; he covers healthcare, insurance ... who average 22 years of industry experience. J.P. Morgan is a well-resourced, diligent, and responsible steward of ...